A Phase II, Double-blinded, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Vitalliver in Patients With Decompensated Cirrhosis
PHASE2CompletedINTERVENTIONAL
Enrollment
90
Participants
Timeline
Start Date
January 31, 2005
Study Completion Date
May 31, 2006
Conditions
Hepatitis BHepatitis CLiver Cirrhosis
Interventions
DRUG
Vitaliver
DRUG
Placebo
Trial Locations (1)
Unknown
Queen Mary Hospital, Hong Kong
All Listed Sponsors
collaborator
Vigconic (International) Ltd.
INDUSTRY
lead
Hospital Authority, Hong Kong
OTHER_GOV
NCT00562783 - A Phase II, Double-blinded, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Vitalliver in Patients With Decompensated Cirrhosis | Biotech Hunter | Biotech Hunter